HK Stock Market Move | JXR (01951) rose more than 4% in early trading, with a net profit attributable to shareholders of 107 million yuan in the first half of the year, focusing on expanding its VIP and international business.

JXR (01951) rose over 4% in early trading. As of the time of publication, it has increased by 2.01%, trading at HKD 2.275, with a transaction volume of HKD 17.8285 million. On the news front, JXR recently released its performance report for the six months ended June 30, 2026, showing revenues of RMB 1.373 billion, a year-on-year increase of 6.57%; the profit attributable to shareholders was RMB 107 million, returning to profitability year-on-year; basic earnings per share were RMB 0.04. The announcement stated that the increase in company revenue was primarily due to the official implementation of California's SB 729 as of 2026 and the successful reserves of doctors over the past three years, leading to a record high in egg retrieval cycles in the first half of the year, with a year-on-year revenue increase of RMB 87.1 million; the development of women's entire lifecycle and reproductive health management strategies contributed to a year-on-year increase of RMB 14.7 million in women's health service revenues. On the business side, following the complete operation of the Shenzhen hospital since the second quarter of 2026, and benefiting from 40 years of medical technological accumulation and hardware upgrades at the new facility, high-net-worth business has already shown results in the first half of 2026, with a 32.5% significant increase in first-time infertility consultations and a year-on-year growth of 6.9 percentage points in VIP penetration rates, reaching 9.2%. The number of first-time patients from Hong Kong increased by 62% year-on-year. In the future, leveraging the geographical advantages of the Guangdong-Hong Kong-Macao Greater Bay Area, the company will focus on enhancing its VIP and international businesses, with high-net-worth operations expected to see rapid growth.